Biogen Inc.: New Data at AAN 2022 Highlight Real-World Evide

Data from NOVA study further support the efficacy and safety of natalizumab IV when administered every six weeks as compared to the approved every four-week dosingAdditional real-world data affirm high

Related Keywords

United States , Cambridge , Cambridgeshire , United Kingdom , American , Maha Radhakrishnan , Charles Weissmann , Walter Gilbert , Heinz Schaller , Shibeshih Belachew , Ashleigh Koss , Mike Hencke , Diroximel Fumarate , Kenneth Murray , Program Database , Commitment To Health , Linkedin , Biogen Digital Health , Twitter , Six Week Administration , Acariahealth Specialty Pharmacy Program , Nasdaq , Exchange Commission , Youtube , Facebook , American Academy Of Neurology , Ms With Digital Health Research , American Academy , Chief Medical Officer , Every Six Week , Unified Commitment , World Analyses Further Demonstrate High Rates , Continues Pursuit , Biogen Digital , Presentations Featured , Extended Interval Dosing , Reduced Risk , Progressive Multifocal Leukoencephalopathy , Updated Analysis , Randomized Controlled Study , Week Dosing , Natalizumab Versus Continued , Week Treatment , Multiple Sclerosis , Natalizumab Treatment , Early Relapsing Remitting Multiple Sclerosis , Real World Analysis Affirms , High Persistence , Adherence Observed , Has High Rates , Real World Adherence , Retrospective Claims Analysis , Relapsing Remitting Multiple Sclerosis , Interim Safety , Efficacy Results , Learning Based Detection , Slowly Expanding Lesions Using Radiomic Features , Cross Sectional Brain , Learning Based Prediction , Pre Lesion Normal Appearing White Matter , Sustain Disease Subtyping , Precision Medicine , Secondary Progressive , Important Safety Information , Boxed Warning , Prescribing Information , Medication Guidefor , Important Safety Informationand , Patient Informationfor , Sir Kenneth Murray , Nobel Prize , Healthy Lives , Private Securities Litigation Reform Act , Biogen , Data , 022 , Highlight , Meal , World , Evidence , Rom , Portfolio , Merging , Research , Disease , Progression ,